NCT00599482

Brief Summary

Most patients with sickle-cell disease have periodic intensely painful episodes. To manage this pain, we are proposing the drinking of at least 500 mL of water followed by far infrared radiation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jan 2008

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

January 11, 2008

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 23, 2008

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2009

Completed
Last Updated

January 5, 2009

Status Verified

January 1, 2009

Enrollment Period

8 months

First QC Date

January 11, 2008

Last Update Submit

January 2, 2009

Conditions

Anemia, Sickle Cell

Keywords

HEMOGLOBIN SC DISEASEHEMOGLOBIN C DISEASESICKLE CELL TRAITTHALASSEMIA

Outcome Measures

Primary Outcomes (1)

  • Pain Management

    40 minutes

Study Arms (1)

1

OTHER

Far Infrared Radiation

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Interventions

Far Infrared Radiation (5μm to 20μm wavelength)RADIATION

Far infrared radiation for 30 to 40 minutes during each session.

1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • People with sickle cell disease

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Centre for Incurable Diseases

Mississauga, Ontario, L5R 3G9, Canada

Location

MeSH Terms

Conditions

Anemia, Sickle CellHemoglobin SC DiseaseHemoglobin C DiseaseSickle Cell TraitThalassemia

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, CongenitalAnemia, HemolyticAnemiaHematologic DiseasesHemic and Lymphatic DiseasesHemoglobinopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Ken Nedd, M.D.

    GAAD Medical Research Institute Inc.

    STUDY CHAIR

  • Kwasi Donyina, Ph.D.

    GAAD Medical Research Institute Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 11, 2008

First Posted

January 23, 2008

Study Start

January 1, 2008

Primary Completion

September 1, 2008

Study Completion

January 1, 2009

Last Updated

January 5, 2009

Record last verified: 2009-01

Locations

CA(1)